Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed Mantle Cell Lymphoma Involving CNS: Two Case Reports and Literature Review

Mantle cell lymphoma (MCL) accounts for 3–10 % of all non-Hodgkin lymphoma variants and is characterized by its aggressive course with frequent relapses and extranodal lesions. Due to more effective systemic chemotherapy and, as a consequence of this, increased life expectancy, relapse rate in MCL i...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Evgenii Olegovich Kunevich, N. N. Nemstsveridze, M. A. Mikhaleva, A. Yu. Kuvshinov, T. V. Ovchinnikova, E. V. Koryakina, S. V. Samarina, K. Yu. Krutikova, S. V. Sidorkevich, S. V. Voloshin
Natura:	Artigo
Lingua:	Russo
Pubblicazione:	Practical Medicine Publishing House 2025-04-01
Serie:	Клиническая онкогематология
Soggetti:	mantle cell lymphoma relapses involving cns ibrutinib bruton tyrosine kinase inhibitors blood-brain barrier
Accesso online:	https://bloodjournal.ru/index.php/coh/article/view/285
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!